Jubilant Pharmova Limited · NSE:JUBLPHARMA

Jubilant Pharmova — Jubilant Life Sciences — Q2 FY2017 Earnings Presentation

24 slides from Jubilant Pharmova's earnings presentation, Oct 27, 2016

1. Slide 1: Financial Results Quarter Ended September 30, 2016

   Financial Results Quarter Ended September 30, 2016

2. Slide 2: Disclaimer

   Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

3. Slide 3: Conference Call Details

   Conference Call Details Date : Thursday, October 27, 2016 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 Secondary Number: +91 22 6746 8354 3940 3977 Available in ‐ Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessi

4. Slide 4: Q2'17 Results Analysis

   eae ZZ Pe J UBIILANT LIFESCIENCES Q2’17 Results Analysis

5. Slide 5: Income Statement – Q2'FY17

   Income Statement – Q2’FY17 Particulars Q2'FY16 Q2'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 1,492 1,419 ‐5% Pharmaceuticals 710 769 8% Life Science Ingredients 754 613 ‐19% Drug Discovery Solutions 27 38 39% Total Expenditure 1,169 1,079 ‐8% Other Income 4 5 10% EBITDA including Othe

6. Slide 6: Financial Highlights – Q2'FY17

   Financial Highlights – Q2’FY17 • Consolidated revenue at Rs. 1,419 Crore • Pharmaceutical revenue at Rs. 769 Crore, contributing 54% to the revenues, up 8% YoY • Life Science Ingredients revenue at Rs. 613 Crore, contributing 43% to the revenues • Drug Discovery Solutions revenue at Rs. 38 Crore, co

7. Slide 7: Pharma Business Highlights – Q2'FY17

   Pharma Business Highlights – Q2’FY17 • Revenues of Rs. 769 Crore, up 8% YoY • Specialty Pharmaceuticals (Sterile Products) revenues decline 5% YoY due to maintenance shutdown of CMO facility; contribute 49% to the sales • Generics revenues grew 25% YoY, led by strong growth in APIs and ROW business

8. Slide 8: Pharma Business Highlights – Q2'FY17

   Pharma Business Highlights – Q2’FY17 Region‐wise Revenue (Rs crs) Q2'FY16 Q2'FY17 Mix % YoY % International 676 706 92% 4% North America 533 516 67% ‐3% Europe & Japan 96 106 14% 10% ROW 47 85 11% 79% India 35 63 8% 82% Income from Operations 710 769 100% 8%  International Revenues grow 4% YoY to R

9. Slide 9: Portfolio of R&D products – Filings and Approvals

   Portfolio of R&D products – Filings and Approvals Product pipeline as on Sept 30, 2016 Dosage (Orals) Sterile including JDI Region Total Filings Approval Pending Total Filings Approval Pending US 72 47 25 12 9 3 Canada 21 19 2 14 14 0 Europe 100 96 4 12 10 2 ROW 596 434 162 44 40 4 Total 789 596 193

10. Slide 10: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals

    Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals  USFDA approval received for Rubyfill; On track for expected launch in Q3 FY17  Filing status as on September 30, 2016: • 7 approved registrations and 2 pending approvals in the US • 14 registrations in Canada which are all

11. Slide 11: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals

    Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals  Orphan Drug I‐131 MIBG – NDA filing in US i. Jubilant has received Orphan drug status with eligibility for accelerated approval ii. Indicated for treatment of paediatric Neuroblastoma, accounting for 6% of cancers in childr

12. Slide 12: Portfolio of Generics – Filings and Approvals

    Portfolio of Generics – Filings and Approvals Dosage (Orals)  Filed 72 ANDAs in the US i. 47 ANDAs have been approved and 25 ANDAs are pending approval ii. We plan to file about 10 ANDAs in FY 17  Made 717 filings in ROW markets including Canada, Europe and Japan i. 549 filings have been approved

13. Slide 13: LSI Business Highlights – Q2'FY17

    LSI Business Highlights – Q2’FY17 Region‐wise Revenue (Rs crs) Q2'FY16 Q2'FY17 Mix % YoY % International 341 241 39% ‐29% Europe, North America and Japan 224 174 28% ‐22% China and ROW 116 67 11% ‐43% India 414 371 61% ‐10% Income from Operations 754 613 100% ‐19% • Revenues at Rs. 613 Crore; Contri

14. Slide 14: Drug Discovery Solutions Business Highlights – Q2'FY17

    Drug Discovery Solutions Business Highlights – Q2’FY17 • Revenues at Rs. 38 Crore, grew 39% YoY; Contributes 3% to total revenues • EBITDA at Rs. (1) Crore, up from Rs. (2) Crore in Q2’16; EBITDA margins at (4)%, up from (6.5)% in Q2’16 • In Proprietary Drug Discovery, the pipeline of novel products

15. Slide 15: Half-Yearly Results Analysis

    Half‐Yearly Results Analysis 14 14

16. Slide 16: Income Statement – H1'FY17

    Income Statement – H1’FY17 Particulars H1'FY16 H1'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 2,977 2,873 ‐3% Pharmaceuticals 1,417 1,524 8% Life Science Ingredients 1,509 1,262 ‐16% Drug Discovery Solutions 52 87 69% Total Expenditure 2,329 2,165 ‐7% Other Income 8 9 11% EBITDA includ

17. Slide 17: Financial Highlights – H1'FY17

    Financial Highlights – H1’FY17 • Consolidated revenue at Rs. 2,873 Crore • Pharmaceuticals revenue at Rs. 1,524 Crore, up 8% YoY, contributing 53% to the revenues • LSI revenue at Rs. 1,262 Crore, contributing 44% to the revenues • Drug Discovery Solutions revenue at Rs. 87 Crore, up 69% YoY, contri

18. Slide 18: Pharma Business Highlights – H1'FY17

    Pharma Business Highlights – H1’FY17 • Revenues of Rs. 1,524 Crores, up 8% YoY • Specialty Pharmaceuticals (Sterile Products) revenues grow 4% YoY; contribute 51% to segment sales • Generics revenues grew 12% YoY, led by strong growth in APIs and ROW business in Solid Dosage Formulations • USFDA ins

19. Slide 19: Pharma Business Highlights – H1'FY17

    Pharma Business Highlights – H1’FY17 Geo‐wise Revenue (Rs crs) H1'FY16 H1'FY17 Mix % YoY % International 1,341 1,411 93% 5% USA & Canada 1,063 1,017 67% ‐4% Europe & Japan 170 225 15% 33% ROW 108 169 11% 56% India 76 113 7% 49% Income from Operations 1,417 1,524 100% 8%  International Revenues grow

20. Slide 20: LSI Business Highlights – H1'FY17

    LSI Business Highlights – H1’FY17 Geo‐wise Revenue (Rs crs) H1'FY16 H1'FY17 Mix % YoY % International 696 537 43% ‐23% Europe, North America and 456 383 30% ‐16% Japan China and ROW 239 154 12% ‐36% India 813 725 57% ‐11% Income from Operations 1,509 1,262 100% ‐16% • Revenues at Rs. 1,262 Crore; Co

21. Slide 21: Drug Discovery Solutions Business Highlights – H1'FY17

    Drug Discovery Solutions Business Highlights – H1’FY17 • Revenues at Rs. 87 Crore, grow 69% YoY; Contributes 3% to total revenues • EBITDA at Rs. 15 Crore, including out‐licensing income of US$ 2 Million, up from Rs. (3) Crore in H1’16 • Proprietary Drug Discovery  Out‐licensing of family of patent

22. Slide 22: Debt Profile

    Debt Profile Particulars 31‐Mar‐16 30‐Jun‐16 30‐Sep‐16 After Bond Issue Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) ($ Mn) Standalone 55 35 35 35 Subsidiaries 320 287 267 417 Total 375 322 302 452 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,422 1,522 1,485 1,160 Subsidiaries 626

23. Slide 23: Outlook

    Outlook  In H2 FY 2017, key initiatives across segments to result in improved performance • In Pharmaceuticals segment, higher profitability is expected on account of: • New product launches in Generics and Specialty • Continued growth in ROW business in Solid Dosage Formulations • Ramp‐up of opera

24. Slide 24: For more information

    For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91‐120‐436 1002 Ph: +91‐22‐6645 1209 E‐mail: ravi_agrawal@jubl.com E‐mail: siddharth@cdr‐india.com For Media: Sudhakar Safaya Siddhartha Bhatnagar Jubilant Life Sciences Limited Perfect

Jubilant Life Sciences — Q2 FY2017 Earnings Presentation on 6ix